[HTML][HTML] The anomalous magnetic moment of the muon in the Standard Model
…, N Cardoso, B Chakraborty, EH Chao, J Charles… - Physics reports, 2020 - Elsevier
We review the present status of the Standard Model calculation of the anomalous magnetic
moment of the muon. This is performed in a perturbative expansion in the fine-structure …
moment of the muon. This is performed in a perturbative expansion in the fine-structure …
[HTML][HTML] Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Background Nivolumab was associated with higher rates of objective response than chemotherapy
in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma…
in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma…
CP violation and the CKM matrix: assessing the impact of the asymmetric B factories
J Charles, A Höcker, H Lacker, S Laplace… - The European Physical …, 2005 - Springer
We present an up-to-date profile of the Cabibbo-Kobayashi-Maskawa matrix with emphasis
on the interpretation of recent CP-violation results from the B factories. For this purpose, we …
on the interpretation of recent CP-violation results from the B factories. For this purpose, we …
[HTML][HTML] Future physics programme of BESIII
…, J Chai, JF Chang, WL Chang, J Charles… - Chinese …, 2020 - iopscience.iop.org
There has recently been a dramatic renewal of interest in hadron spectroscopy and charm
physics. This renaissance has been driven in part by the discovery of a plethora of …
physics. This renaissance has been driven in part by the discovery of a plethora of …
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
…, J Zhang, MG Ziegler, SR Zwart, JB Charles… - Science, 2019 - science.org
INTRODUCTION To date, 559 humans have been flown into space, but long-duration (>300
days) missions are rare (n = 8 total). Long-duration missions that will take humans to Mars …
days) missions are rare (n = 8 total). Long-duration missions that will take humans to Mars …
Heavy-to-light form factors in the final hadron large energy limit of QCD
J Charles, A Le Yaouanc, L Oliver, O Pene, JC Raynal - Physical Review D, 1999 - APS
We argue that the large energy effective theory (LEET), originally proposed by Dugan and
Grinstein, is applicable to exclusive semileptonic, radiative, and rare heavy-to-light transitions …
Grinstein, is applicable to exclusive semileptonic, radiative, and rare heavy-to-light transitions …
[HTML][HTML] The genome sequence of the entomopathogenic bacterium Photorhabdus luminescens
…, C Boursaux-Eude, M Chandler, JF Charles… - Nature …, 2003 - nature.com
Photorhabdus luminescens is a symbiont of nematodes and a broad-spectrum insect pathogen.
The complete genome sequence of strain TT01 is 5,688,987 base pairs (bp) long and …
The complete genome sequence of strain TT01 is 5,688,987 base pairs (bp) long and …
Flowing convnets for human pose estimation in videos
The objective of this work is human pose estimation in videos, where multiple frames are
available. We investigate a ConvNet architecture that is able to benefit from temporal context by …
available. We investigate a ConvNet architecture that is able to benefit from temporal context by …
Predictions of selected flavor observables within the standard model
J Charles, O Deschamps, S Descotes-Genon, R Itoh… - Physical Review D, 2011 - APS
This paper gathers a selection of standard model predictions issued from the metrology of
the Cabibbo-Kobayashi-Maskawa parameters performed by the CKMfitter group. The …
the Cabibbo-Kobayashi-Maskawa parameters performed by the CKMfitter group. The …
[HTML][HTML] Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
…, P Mohr, I Marquez-Rodas, J Charles… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional
therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint …
therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint …